CLS again releases TRANBERG® sterile disposable products on the European market and enters into an agreement with two additional suppliers of sterilization services

Clinical Laserthermia Systems AB (publ) (CLS), which develops advanced innovative products for high-precision image-guided laser ablation, today announces that the company is again releasing its entire range of TRANBERG® sterile disposable products on the European market, following final approval from CLS notified body TüV Süd. CLS has also entered into agreements with two additional suppliers of sterilization services, Steril Verona S.r.l and Sterigenics International Inc.

-          “With the release of our sterile disposable products on the European market, which takes place after we released our products on the US market last week, we have now resumed the company's sales in all markets where we are active. By entering into additional supplier agreements, we have also increased our delivery capacity and flexibility, which reduces the risk of future interruptions", says Dan Mogren, acting CEO of CLS.
 

The release comes after CLS recalled all sterile disposable products in April as a result of the company's previous provider of sterilization services being stripped of its certificate. Since then, CLS has signed agreements with a total of three new suppliers of sterilization services. In addition to the new suppliers Steril Verona S.r.l and Sterigenics International Inc, CLS already has Rose GmbH as a supplier.

 

This press release has been translated from Swedish. The Swedish text shall govern for all purposes and prevail in case of any discrepancy with the English version.

Contact information:
Dan J. Mogren, acting CEO Clinical Laserthermia Systems AB (publ)
Phone: +46 – (0)705 – 90 11 40 E-mail: dan.mogren@clinicallaser.com
 

Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy System, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and for treatment with imILT®, the Company's interstitial laser thermotherapy with potential immunostimulatory effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB, Phone: +46 8 528 00 399. E-mail: info@fnca.se. For more information about CLS, please visit the Company's website: www.clinicallaser.se

Subscribe

Documents & Links